Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection

被引:42
|
作者
Meyers, CD
Kashyap, ML
机构
[1] Vet Affairs Hlth Care Syst, Atherosclerosis Res Ctr, Long Beach, CA 90822 USA
[2] Vet Affairs Hlth Care Syst, Gerontol Sect, Long Beach, CA 90822 USA
[3] Univ Calif Irvine, Div Cardiol, Irvine, CA USA
关键词
high-density lipoproteins; apolipoprotein Al; reverse cholesterol transport; atherosclerosis;
D O I
10.1097/01.hco.0000126582.27767.87
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Despite the best efforts in reduction of low-density lipoprotein cholesterol, most cardiovascular events are not being prevented. Because high-density lipoprotein (HDL) promotes reverse cholesterol transport and other antiatherogenic effects, interventions aimed at raising HDL cholesterol or mimicking its beneficial effects may greatly improve treatment and prevention of cardiovascular disease. This article reviews the antiatherogenic effects of HDL, recent insights into the mechanisms of action of currently available, and emerging HDL-based therapies. Recent findings New insights into the basic science of HDIL function and metabolism (such as the discovery of beta-chain ATIP synthase as a hepatic catabolic HDL receptor) are further characterizing the importance of HDIL in atheroprotection and identifying novel targets of drug development. Nicotinic acid, fibrates, statins, and thiazolidinediones not only increase HDIL cholesterol but also alter HDIL subpopulation size and composition. Furthermore, these drugs promote direct antiatherogenic effects of HDL (antioxidation, anti-inflammation, antithrombotic effects, endothelial stabilization). Emerging HDL-raising therapies (such as cholesteryl ester transfer protein inhibitors and 1,2-dimyristoyl-sn-glycero-phosphocholine) and novel interventions that mimic HDL's beneficial effects (such as apolipoprotein Al-milano. and apolipoprotein Al mimetic peptides) are proving beneficial in animal and human studies. Summary An understanding of the atheroprotective mechanisms of HDL is essential for the rational use of currently available drugs and directed development of new drugs. Increasing total HDL cholesterol may not be as important as increasing the functional properties of HDL. Cardiovascular disease treatment and prevention can be improved by combining current low-density lipoprotein-based strategies with effective HDL-based interventions.
引用
收藏
页码:366 / 373
页数:8
相关论文
共 50 条
  • [1] High-density lipoproteins and atherosclerosis
    Rader, DJ
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (8A): : 62I - 70I
  • [2] HIGH-DENSITY LIPOPROTEINS AND ATHEROSCLEROSIS
    ASSMANN, G
    SCHULTE, H
    FUNKE, H
    VONECKARDSTEIN, A
    SCHMITZ, G
    ROBENEK, H
    ATHEROSCLEROSIS VIII, 1989, 817 : 341 - 351
  • [3] HIGH-DENSITY LIPOPROTEINS AND ATHEROSCLEROSIS
    MILLER, GJ
    ANNUAL REVIEW OF MEDICINE, 1980, 31 : 97 - 108
  • [4] HIGH-DENSITY LIPOPROTEINS AND ATHEROSCLEROSIS
    GUREWICH, V
    LIPINSKA, I
    LIPINSKI, B
    NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (20): : 1274 - 1275
  • [5] HIGH-DENSITY LIPOPROTEINS AND ATHEROSCLEROSIS - REPLY
    LEES, RS
    LEES, AM
    NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (20): : 1275 - 1275
  • [6] Atherosclerosis regression and high-density lipoproteins
    Lee, Justin M. S.
    Choudhury, Robin P.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (09) : 1325 - 1334
  • [7] HIGH-DENSITY LIPOPROTEINS, REVERSE CHOLESTEROL TRANSPORT AND ATHEROSCLEROSIS - RECENT DEVELOPMENTS
    BERGER, GMB
    SOUTH AFRICAN MEDICAL JOURNAL, 1984, 65 (13): : 503 - 506
  • [8] EFFECTS OF PHARMACOLOGIC INTERVENTION ON HIGH-DENSITY LIPOPROTEINS - DISCUSSION
    HOWARD, A
    MANNINEN, V
    GOTTO, AM
    MARCUS, E
    LITTLE, JA
    LEWIS, B
    PAOLETTI, R
    GLUECK, CJ
    PICKERING, JE
    FERGAMEN, O
    NIKKILA, EA
    RIFKIND
    WILLIAMS, S
    SCHLIERF, G
    MANHEIM
    BERGER, GMB
    AMERICAN JOURNAL OF CARDIOLOGY, 1983, 52 (04): : B41 - B43
  • [9] The protective role of high-density lipoproteins in atherosclerosis
    She, MP
    Wang, ZL
    EXPERIMENTAL GERONTOLOGY, 1999, 34 (04) : 539 - 548
  • [10] The antioxidant properties of high-density lipoproteins in atherosclerosis
    Mackness, B.
    Mackness, M.
    PANMINERVA MEDICA, 2012, 54 (02) : 83 - 90